CD39
Exo-nucleotidase
CD39 is a key enzyme in removing ATP from the tumor microenvironment; increased ATP may enhance the adaptive immune response against tumors.1
Additional undisclosed targets.
AXL Inhibitor
Tyrosine kinase
AXL overexpression is associated with tumor resistance to chemotherapy and immunotherapy drugs.3
Additional undisclosed targets.
References: 1. Moesta et al. Targeting CD39 in Cancer. Nature Reviews Immunology volume 20, pages739–755 (2020). 2. Murugesan T, Rajajeyabalachandran G, Kumar S, Nagaraju S, Kumar S. Targeting HIF-2α as therapy for advanced cancers. Drug Discov Today. 2018;23(7):1444-1451. 3. Axelrod HD, Valkenburg KC, Amend SR, et al. AXL is a putative tumor suppressor and dormancy regulator in prostate cancer. Mol Cancer Res. 2019;17(2):356-369.
